Back to top
February 7, 2018
FDA grants breakthrough therapy designation for Dravet syndrome treatment
Research, Treatments, Pediatric Epilepsies

The FDA has granted Zogenix Inc. breakthrough therapy designation for low-dose fenfluramine use to treat seizures related to Dravet syndrome, according to a press release issued by the company.

“We are very pleased that the FDA has granted breakthrough therapy designation based on the efficacy and safety results from Study 1 reported in the fall of 2017,” Gail M. Farfel, PhD, chief development officer of Zogenix, said in the release. “We look forward to working closely with the FDA as we conclude our phase 3 clinical program in Dravet syndrome, a rare and catastrophic form of childhood epilepsy.

ZX008 can also be used for the treatment of Lennox-Gastaut syndrome, according to the release This form of epilepsy is also severe and begins in childhood. Those who have this condition are likely to also have intellectual disability.

Learn More

 

Related News

May 12, 2018
Rush is First to Use Microburst Vagus Nerve Stimulation for...

Epilepsy patients who have not responded to standard drug treatments may benefit from a new therapy that delivers high frequency bursts of...

Read More
May 10, 2018
Study: Efficacy and Safety of Ketogenic Diet for Treatment...

This series suggests efficacy and safety of ketogenic diet (KD) for treatment of pediatric convulsive refractory status epilepticus (RSE).

Read More
May 9, 2018
Study: Risk Assessment of In-Hospital Mortality of Patients...

The in-hospital mortality of people with epilepsy increased remarkably with age, and this parameter was predominant in male patients, according...

Read More